Session 3: Small Molecule Metabolites in Drug Discovery and Development
Chairs: Faye Vazvaei-Smith, Wenkui Li, Carley Heck, and Scott Obach
Industry Perspective on the Value of ADME Studies and Drug Metabolites
Douglas Spracklin, Pfizer
Drug Metabolites and Their Roles in Drug-drug Interactions
Xinning Yang, U.S. Food and Drug Administration
Vignette 1
Simone Schadt, Roche
Kenichi Umehara, Roche
Vignette 2
Sekhar Surapaneni, Bristol Myers Squibb
Roundtable Discussion with Speakers
Key:
Complete
Next
Failed
Available
Locked
Session 3: Small Molecule Metabolites in Drug Discovery and Development
Recorded 03/03/2023 | 60 minutes
Recorded 03/03/2023 | 60 minutes
Time Stamps:
0:00 - Welcome and Introduction
4:10 - Douglas Spracklin's Presentation: Industry Perspective on the Value of ADME Studies and Drug Metabolites
40:50 - Xinning Yang's Presentation: Drug Metabolites and Their Roles in Drug-drug Interactions
1:31:13 - Simone Schadt's and Kenichi Umehara's Presentation: Vignette 1
2:15:30 - Sekhar Surapaneni's Presentation: Vignette 2
3:05:20 - Panel Discussion
3:46:20 - Closing Slides